Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ITPR2 antisense RNA 2 (ITPR2-AS2) is a long non-coding RNA transcribed antisense to the ITPR2 gene. It is not a canonical therapeutic drug target, but instead acts as a gene regulatory RNA. Evidence suggests it can regulate the expression of the ITPR2 gene, possibly through mechanisms like competitive endogenous RNA (ceRNA) activity, interacting with microRNAs or other gene-regulatory machinery. ITPR2-AS2 has been implicated in the regulation of ITPR2 expression in the context of neurodegenerative diseases such as Alzheimer's disease, but it is not known to be directly involved in signal transduction, cell surface receptor activity, or enzymatic function typical of established drug targets. There are currently no drugs or direct therapeutic interventions targeting ITPR2-AS2, and it is not in use as a disease biomarker. Summary: ITPR2-AS2 is not a traditional drug target but is a regulatory non-coding RNA whose primary biological relevance is indirect, via modulation of the ITPR2 gene and possibly affecting disease pathways in neurodegeneration. Most structured drug and therapeutic target information is not applicable.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ITPR2 antisense RNA 2 (ITPR2-AS2).